Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain stimulation study seeks clues to lasting depression relief

NCT ID NCT07684911

Knowledge-focused Sponsor: Hospital Center Guillaume Régnier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study follows people with treatment-resistant depression who have already responded to transcranial magnetic stimulation (TMS). Researchers want to understand how long the antidepressant effect lasts and what factors—like brain plasticity, heart-brain coupling, or inflammation—might predict relapse. Participants receive standard TMS and are monitored with questionnaires, heart rate recordings, blood tests, and MRI scans. The goal is to find biomarkers that could guide personalized treatment plans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If successful, this could help doctors predict how long TMS benefits last and personalize treatment schedules to prevent relapse.
What could go wrong
This is a small observational study, not a treatment trial. It may not identify reliable predictors, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing a TMS course as part of clinical care at the Adult Psychiatry University Hospital Unit of the Guillaume Régnier Hospital Center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 or older. * Patients who have experienced treatment-resistant unipolar or bipolar depression and responded to a previous TMS course (response defined by a 50% reduction in MADRS score). * Sufficient command of French to complete questionnaires and follow instructions during MRI assessments and TMS treatments. * Willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study staff about adverse events and other clinically relevant information. * Patients who have expressed their informed written consent to participate in the study. * Person affiliated with a social welfare scheme or other scheme. Non-inclusion Criteria: * Current psychiatric comorbidity (suicidal risk, psychotic episode). * Unstable somatic pathology: active cancer, unstabilized endocrinological pathology, untreated sleep apnea. * For neuroimaging: Contraindications to magnetic resonance imaging (MRI) such as ferromagnetic metal in the body or severe claustrophobia * Adults under legal protection (legal guardianship, conservatorship, trusteeship), persons deprived of their liberty * Pregnancy or breast-feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar depression bipolar disorder Inflammation major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder Depression, bipolar Depression, unipolar

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Guillaume Régnier

    RECRUITING

    Rennes, 35700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.